A 43-year-old with obesity (BMI 37) and type 2 diabetes has A1C 9.1% despite metformin and lifestyle. No ASCVD or CKD. Per ADA 2025, which is a reason...

Question

A 43-year-old with obesity (BMI 37) and type 2 diabetes has A1C 9.1% despite metformin and lifestyle. No ASCVD or CKD. Per ADA 2025, which is a reasonable next choice prioritizing weight loss and glycemic efficacy?

Accepted Answer

GLP-1 receptor agonist

Answer

Pioglitazone

Answer

Basal insulin immediately

Answer

DPP-4 inhibitor

Answer

Sulfonylurea

us-abfm MCQ (SBA): Type 2 Diabetes Therapy

A 43-year-old with obesity (BMI 37) and type 2 diabetes has A1C 9.1% despite metformin and lifestyle. No ASCVD or CKD. Per ADA 2025, which is a reasonable next choice prioritizing weight loss and glycemic efficacy?